Persistent pulmonary hypertension (PPH), which has high morbidity and mortality due to the difficulty in treatment, is an important disease of the newborn period. A wide range of vasodilator drugs have been used in the treatment as the primary event is pulmonary vasoconstriction in the pathogenesis. When iloprost is administered via aerosolization to patients with pulmonary hypertension, it induces selective vasodilatation on pulmonary vessels. Records of nine newborn infants diagnosed as PPH and treated with inhaled iloprost treatment were resrospectively evaluated. Mean duration of inhaled iloprost treatment was 4.7 ± 4.1 days (1-15 days). No patient receiving inhaled iloprost had a decrease in systemic blood pressure or oxygen saturation. No respiratory difficulty was observed during administration. As inhaled nitric oxide cannot be applied in our country, the use of iloprost may be preferred instead in the effective treatment of PPH in the newborn period owing to its low systemic side effects, high tolerability and reliability.

Keywords: yenidoğan, pulmoner hipertansiyon, inhale iloprost, newborn, pulmonary hypertension, inhaled iloprost